International Clinical Trial: A Phase II, Multicenter, Open-Label, Single-Arm Study of Durvalumab in Combination With Gemcitabine and Liposomal Irinotecan (nal-IRI) as First-Line Therapy in Patients With Advanced Biliary Tract Cancer

Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119377) titled 'A Phase II, Multicenter, Open-Label, Single-Arm Study of Durvalumab in Combination With Gemcitabine and Liposomal Irinotecan (nal-IRI) as First-Line Therapy in Patients With Advanced Biliary Tract Cancer' on Feb. 26.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Condition: Advanced Biliary Tract Cancer

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-03-01

Target Sample Size: Single-arm:36;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=3100...